RT Journal Article
SR Electronic
T1 Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.24.21253087
DO 10.1101/2021.05.24.21253087
A1 Wimmers, Florian
A1 Donato, Michele
A1 Kuo, Alex
A1 Ashuach, Tal
A1 Gupta, Shakti
A1 Li, Chunfeng
A1 Dvorak, Mai
A1 Foecke, Mariko Hinton
A1 Chang, Sarah E.
A1 De Jong, Sanne E.
A1 Maecker, Holden T.
A1 van der Most, Robbert
A1 Cheung, Peggie
A1 Cortese, Mario
A1 Hagan, Thomas
A1 Bosinger, Steven E.
A1 Davis, Mark
A1 Rouphael, Nadine
A1 Subramaniam, Shankar
A1 Yosef, Nir
A1 Utz, Paul J.
A1 Khatri, Purvesh
A1 Pulendran, Bali
YR 2021
UL http://medrxiv.org/content/early/2021/05/26/2021.05.24.21253087.abstract
AB Emerging evidence indicates a fundamental role for the epigenome in immunity. Here, we used a systems biology approach to map the epigenomic and transcriptional landscape of immunity to influenza vaccination in humans at the single-cell level. Vaccination against seasonal influenza resulted in persistently reduced H3K27ac in monocytes and myeloid dendritic cells, which was associated with impaired cytokine responses to TLR stimulation. Single cell ATAC-seq analysis of 120,305 single cells revealed an epigenomically distinct subcluster of monocytes with reduced chromatin accessibility at AP-1-targeted loci after vaccination. Similar effects were also observed in response to vaccination with the AS03-adjuvanted H5N1 pandemic influenza vaccine. However, this vaccine also stimulated persistently increased chromatin accessibility at loci targeted by interferon response factors (IRFs). This was associated with elevated expression of antiviral genes and type 1 IFN production and heightened resistance to infection with the heterologous viruses Zika and Dengue. These results demonstrate that influenza vaccines stimulate persistent epigenomic remodeling of the innate immune system. Notably, AS03-adjuvanted vaccination remodeled the epigenome of myeloid cells to confer heightened resistance against heterologous viruses, revealing its potentially unappreciated role as an epigenetic adjuvant.Competing Interest StatementBP serves on the External Immunology Network of GSK. RvdM is an employee of the GSK group of companies and holds shares in the GSK group of companies. The remaining authors declare no competing interests.Clinical TrialNCT02154061, NCT01910519Funding StatementThis work was supported by NIH grants HIPC 4U19AI090023-11 (to B.P.) and CCIH 5U19AI057266-17 (to B.P). Funding for this study was also provided by GlaxoSmithKline Biologicals SA [NCT01910519]. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were conducted in Atlanta, GA. Written informed consent was obtained from each subject and protocols were approved by Institutional Review Boards of Emory University. Samples from healthy subjects were collected at Stanford Blood Center. All subjects provided a confidential medical history card and completed informed consent to donate blood for clinical or research uses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEpiTOF data is available at: will be available upon publication. Bulk ATAC-seq and RNA-seq data is available here: will be available upon publication. ScATAC-seq and scRNA-seq data are deposited at: will be available upon publication.